Beyeler Mirjam, Waldispuhl Severa, Strobel Klaus, Joller-Jemelka Helen I, Burg Gunter, Dummer Reinhard
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Dermatology. 2006;213(3):187-91. doi: 10.1159/000095034.
Early detection of melanoma recurrence is essential for the patient's prognosis. The serum S100 level may be a useful tool to detect relapse early.
To compare the efficacy of imaging techniques and serum S100 in the early detection of melanoma progression. This is the first report of a comparison of a serum marker with an imaging tool in the follow-up of melanoma patients.
From 1992 to 2003, we screened 192 patients suffering from melanoma recurrence after a disease-free interval. Of those, 127 patients were identified whose S100 levels had been assessed parallel to imaging procedures.
Serum S100 was elevated in 37% of patients at the time of relapse. In stage III, 32% of the patients had elevated S100 levels whereas in case of progression to stage IV, 48% of the patients presented with increased S100. In 5.5% of patients, S100 was the first indicator of disease progression. Imaging procedures lead to detection of melanoma recurrence in 26.8%.
A rising level of serum S100 is a specific and sensitive marker of melanoma progression.
黑色素瘤复发的早期检测对患者的预后至关重要。血清S100水平可能是早期检测复发的有用工具。
比较成像技术和血清S100在黑色素瘤进展早期检测中的效果。这是黑色素瘤患者随访中血清标志物与成像工具比较的首份报告。
1992年至2003年,我们筛查了192例在无病间隔期后出现黑色素瘤复发的患者。其中,127例患者的S100水平在进行成像检查的同时进行了评估。
复发时37%的患者血清S100升高。在III期,32%的患者S100水平升高,而进展至IV期时,48%的患者S100升高。5.5%的患者中,S100是疾病进展的首个指标。成像检查发现26.8%的黑色素瘤复发。
血清S100水平升高是黑色素瘤进展的特异性和敏感性标志物。